Literature DB >> 18709982

[Immunosuppressive therapy with antithymocyte globulin and cyclosporine for paroxysmal nocturnal hemoglobinuria].

Hideki Nakasone1, Kimiko Iijima, Hiroki Asano, Fumihiko Nakamura, Michiko Kida, Koji Izutsu, Akio Urabe, Kensuke Usuki.   

Abstract

Immunosuppressive therapy (IST) for paroxysmal nocturnal hemoglobinuria (PNH) has been infrequently reported. Four PNH cases were treated with antithymocyte globulin (ATG) at our center. We assessed and reviewed the efficacy and safety of IST for PNH. ATG therapy was performed for progression of cytopenia in 3 classical-type and 1 marrow failure-type PNH cases. ATG was administered at a dose of 15 mg/kg for 5 consecutive days. Hydration and anticoagulant therapy were given as prophylaxis for thrombosis during ATG therapy. Cyclosporine was also given to the 3 classical-type PNH patients. Three patients showed hemolytic exacerbation and thrombocytopenia during ATG administration, and all needed to receive transfusions of red blood cells and platelets; however, renal failure and thrombosis did not occur. Anemia improved in all cases within 1 year, but thereafter, recurred in 2 cases. ATG therapy is a choice of treatment for PNH, although its mechanism remains unknown.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18709982

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  2 in total

1.  Rescue of Glycosylphosphatidylinositol-Anchored Protein Biosynthesis Using Synthetic Glycosylphosphatidylinositol Oligosaccharides.

Authors:  Paula A Guerrero; Yoshiko Murakami; Ankita Malik; Peter H Seeberger; Taroh Kinoshita; Daniel Varón Silva
Journal:  ACS Chem Biol       Date:  2021-10-07       Impact factor: 5.100

Review 2.  The Role of T Lymphocytes in the Pathogenesis of Paroxysmal Nocturnal Hemoglobinuria.

Authors:  Chenyuan Li; Xifeng Dong; Huaquan Wang; Zonghong Shao
Journal:  Front Immunol       Date:  2021-12-24       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.